The FDA's priority review of epcoritamab-bysp, a collaborative effort between AbbVie and Genmab, signifies a potential breakthrough in the treatment of relapsed/refractory follicular lymphoma. This development could enhance AbbVie's position in the oncology market, likely leading to a positive short-term impact on its stock price due to increased investor optimism about the drug's commercial prospects.

The FDA granting priority review for epcoritamab-bysp, developed by Genmab in partnership with AbbVie, is a critical step forward in the treatment of relapsed/refractory follicular lymphoma. This achievement not only highlights the potential of Genmab's pipeline but also is likely to positively influence its stock price in the short term due to the anticipated commercial success of the drug.